πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12144826

Methods of treating EGFRvIII expressing glioblastomas

The Regents of the University of California Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144876

Security mechanisms for radiopharmaceutical elution system and elution process

Jubilant Draximage Inc. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144881

Cosmetic composition containing Ξ±-mangostin, method for preparation, and uses thereof

CHINA PHARMACEUTICAL UNIVERSITY Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144813

PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

Cardiff Oncology, Inc. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144864

Tubulysins and protein-tubulysin conjugates

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144815

Use of aprepitant for treating Alzheimer's disease

Hoth Therapeutics, Inc. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144843

Methods and compositions for modulating myofibroblast activities

The Regents of the University of California Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12145944

Imidazopyrimidines as EED inhibitors and the use thereof

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144868

Muscle targeting complexes and uses thereof for treating dystrophinopathies

Dyne Therapeutics, Inc. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144800

Inhibiting germination of Clostridium perfringens spores to reduce necrotic enteritis

THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144802

Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144801

Methods and compositions for treatment of epileptic disorders

OVID THERAPEUTICS INC. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144812

Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators

Corcept Therapeutics Incorporated Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144788

Visual cycle modulators

The United States Government as Represented by The Department of Veteran Affairs Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144828

Human Kynureninase enzymes and uses thereof

The Board of Regents of the University of Texas System Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144869

Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and

Sutro Biopharma, Inc. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144867

Muscle targeting complexes and uses thereof for treating dystrophinopathies

Dyne Therapeutics, Inc. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12146139

Oligonucleotide interference treatments of prostate cancer

The Board of Regents of the University of Oklahoma Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144809

Treatment of prostate cancer

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144877

Graphene-based multifunctional cosmetic compositions

Northwestern University Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12145943

Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)py

ACTUATE THERAPEUTICS INC. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12145941

Heterocyclic antiviral agents

Enanta Pharmaceuticals, Inc. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12139546

Methods of treating urea cycle disorders by interfering with glucagon receptor signaling

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12139543

Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to de

CytomX Therapeutics, Inc. Β· Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted